Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TRC051384 HCl 是热休克蛋白 Hsp70 的诱导剂,可激活热休克因子-1 并增强神经元和神经胶质细胞中 Hsp72 的表达。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 449 | 现货 | ||
2 mg | ¥ 632 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,830 | 现货 | ||
25 mg | ¥ 3,980 | 现货 | ||
50 mg | ¥ 7,320 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
200 mg | ¥ 13,300 | 现货 | ||
500 mg | ¥ 19,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | TRC051384 HCl is an inducer of heat shock protein Hsp70, activating heat shock factor-1 and enhancing Hsp72 expression in neurons and glial cells. |
体内活性 | TRC051384, a novel compound belonging to substituted 2-propen-1-one class is a potent inducer of heat shock protein 70 (HSP70).Treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia.?Significant improvement in survival (50% by day 2 and 67.3% by day 7) was observed with TRC051384 treatment initiated at 4 hours after ischemia onset.?Induction of HSP70 by TRC051384 involves HSF1 activation and results in elevated chaperone and anti-inflammatory activity.?These results show that TRC051384 has the potential to be developed as a novel pharmacological agent for the treatment of ischemic stroke. |
动物实验 | Focal cerebral ischemia was produced in rats by occluding the MCA using the intra luminal suture technique.?Rats subjected to 2 hours focal cerebral ischemia were administered by intra-peritoneal route, TRC051384 or vehicle every 2 hours for 48 hours, from 4th hour or 8th hour after onset of ischemia.?Progression of infarct and edema was assessed up to 48 hours post ischemic insult using magnetic resonance imaging and the neurological disability and survival studied till 7 days. |
分子量 | 502 |
分子式 | C25H32ClN5O4 |
CAS No. | 1333327-56-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (119.52 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.992 mL | 9.9602 mL | 19.9203 mL | 49.8008 mL |
5 mM | 0.3984 mL | 1.992 mL | 3.9841 mL | 9.9602 mL | |
10 mM | 0.1992 mL | 0.996 mL | 1.992 mL | 4.9801 mL | |
20 mM | 0.0996 mL | 0.498 mL | 0.996 mL | 2.49 mL | |
50 mM | 0.0398 mL | 0.1992 mL | 0.3984 mL | 0.996 mL | |
100 mM | 0.0199 mL | 0.0996 mL | 0.1992 mL | 0.498 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TRC051384 HCl 1333327-56-2 Cytoskeletal Signaling Metabolism HSP TRC051384 TRC 051384 TRC-051384 Inhibitor inhibitor inhibit